Brief: FDA Approves New Leqembi Subcutaneous Dosing Regimen For Alzheimer's
13/07/2026 19:12
BRIEF-FDA Approves New Leqembi Subcutaneous Dosing Regimen For Alzheimer's July 13 (Reuters) - FDA:
APPROVES NEW STARTING DOSAGE REGIMEN FOR LEQEMBI SUBCUTANEOUS FORMULATION FOR ALZHEIMER’S DISEASE TREATMENT
Further company coverage: BIIB.O
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China